Prostate cancer gene therapy - Mayne
Alternative Names: FP 253Latest Information Update: 24 Oct 2021
At a glance
- Originator Symbion Health
- Class Antineoplastics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer